Patents Assigned to Roche GlycArt AG
  • BISPECIFIC ANTIBODIES SPECIFIC FOR T-CELL ACTIVATING ANTIGENS AND A TUMOR ANTIGEN AND METHODS OF USE
    Publication number: 20150274845
    Abstract: The present invention relates to bispecific antibodies that specifically bind a T-cell activating antigen and a Tumor Antigen (TA), comprising a first Fab fragment and a second Fab fragment, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged; and wherein the bispecific antibody does not comprise a Fc domain; methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: May 5, 2014
    Publication date: October 1, 2015
    Applicant: Roche Glycart AG
    Inventors: Peter Bruenker, Tanja Fauti, Christiane Jaeger, Christian Klein, Pablo Umana
  • COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A mTOR INHIBITOR
    Publication number: 20150265703
    Abstract: The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a mTOR inhibitor for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a mTOR inhibitor such as Temsirolimus or Everolimus.
    Type: Application
    Filed: June 4, 2015
    Publication date: September 24, 2015
    Applicant: ROCHE GLYCART AG
    Inventors: Frank Herting, Christian Klein
  • ANTIBODY FC VARIANTS
    Publication number: 20150239981
    Abstract: The invention relates to engineered polypeptides comprising Fc variants and their uses. More specifically, Fc variants are described exhibiting reduced effector function. These variants cause a benefit for a patient suffering from a disease which could be treated with an antibody for which it is desirable to reduce the effector function elicited by antibodies.
    Type: Application
    Filed: January 22, 2015
    Publication date: August 27, 2015
    Applicant: Roche Glycart AG
    Inventors: Monika BAEHNER, Stefan JENEWEIN, Manfred KUBBIES, Ekkehard MOESSNER, Tilman SCHLOTHAUER
  • Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
    Patent number: 9074008
    Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
    Type: Grant
    Filed: August 17, 2012
    Date of Patent: July 7, 2015
    Assignee: Roche GlycArt AG
    Inventors: Pablo Umaña, Ekkehard Mössner
  • Antibodies to carcinoembryonic antigen (CEA), methods of making same, and uses thereof
    Patent number: 9068008
    Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies or variants thereof specific for cell surface or membrane bound human CEA. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
    Type: Grant
    Filed: August 31, 2010
    Date of Patent: June 30, 2015
    Assignee: Roche Glycart AG
    Inventors: Ekkehard Mössner, Thomas U. Hofer, Ralf Jörg Hosse, Pablo Umaña
  • Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
    Patent number: 9068005
    Abstract: The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that includes a region equivalent to the Fc region of an immunoglobulin, with enhanced Fc-mediated cellular cytotoxicity.
    Type: Grant
    Filed: March 23, 2009
    Date of Patent: June 30, 2015
    Assignee: Roche GlycArt AG
    Inventors: Pablo Umaña, Joël Jean-Mairet, M. Sean Bailey
  • Anti-FAP antibodies and methods of use
    Patent number: 9011847
    Abstract: The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same.
    Type: Grant
    Filed: August 9, 2011
    Date of Patent: April 21, 2015
    Assignee: Roche Glycart, AG
    Inventors: Marina Bacac, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umaña
  • Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
    Patent number: 8999324
    Abstract: The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to glycosylation engineering to generate proteins with improved therapeutic properties, including antibodies with increased antibody-dependent cellular cytotoxicity.
    Type: Grant
    Filed: August 2, 2011
    Date of Patent: April 7, 2015
    Assignee: Roche GlycArt AG
    Inventors: Pablo Umaña, Joël Jean-Mairet
  • COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH BENDAMUSTINE
    Publication number: 20150093376
    Abstract: The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with bendamustine for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and bendamustine.
    Type: Application
    Filed: May 8, 2014
    Publication date: April 2, 2015
    Applicant: ROCHE GLYCART AG
    Inventors: FRANK HERTING, CHRISTIAN KLEIN
  • COMBINATION THERAPY
    Publication number: 20150079023
    Abstract: The present invention is directed to the combination therapy of an afucosylated antibody specifically binding to a tumor-antigen with human IL-15 for the treatment of cancer.
    Type: Application
    Filed: April 16, 2014
    Publication date: March 19, 2015
    Applicant: ROCHE GLYCART AG
    Inventors: CHRISTIAN KLEIN, EMILIE LAPREVOTTE, ANNE QUILLET-MARY
  • COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH FLUDARABINE AND/OR MITOXANTRONE
    Publication number: 20150079073
    Abstract: The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with fludarabine and/or mitoxantrone for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody with fludarabine and/or mitoxantrone.
    Type: Application
    Filed: April 11, 2014
    Publication date: March 19, 2015
    Applicant: Roche Glycart AG
    Inventors: MARTIN DREYLING, DANIEL ALEXANDER HEINRICH, FRANK HERTING, CHRISTIAN KLEIN
  • COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A mTOR INHIBITOR
    Publication number: 20150071911
    Abstract: The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a mTOR inhibitor for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a mTOR inhibitor such as Temsirolimus or Everolimus.
    Type: Application
    Filed: March 31, 2014
    Publication date: March 12, 2015
    Applicant: ROCHE GLYCART AG
    Inventors: FRANK HERTING, CHRISTIAN KLEIN
  • Antibody Fc variants
    Patent number: 8969526
    Abstract: The invention relates to engineered polypeptides comprising Fc variants and their uses. More specifically, Fc variants are described exhibiting reduced effector function. These variants cause a benefit for a patient suffering from a disease which could be treated with an antibody for which it is desirable to reduce the effector function elicited by antibodies.
    Type: Grant
    Filed: March 27, 2012
    Date of Patent: March 3, 2015
    Assignee: Roche Glycart AG
    Inventors: Monika Baehner, Stefan Jenewein, Manfred Kubbies, Ekkehard Moessner, Tilman Schlothauer
  • ANTI-HER3 ANTIBODIES AND USES THEREOF
    Publication number: 20140377272
    Abstract: The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: September 8, 2014
    Publication date: December 25, 2014
    Applicant: ROCHE GLYCART AG
    Inventors: Birgit Bossenmaier, Nikolaos Dimoudis, Thomas Friess, Guy Georges, Irene Kolm, Hans-Willi Krell, Valeria Lifke, Ekkehard Moessner
  • ANTI-HER3 ANTIBODIES AND USES THEREOF
    Publication number: 20140377273
    Abstract: The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: September 8, 2014
    Publication date: December 25, 2014
    Applicant: ROCHE GLYCART AG
    Inventors: Birgit Bossenmaier, Nikolaos Dimoudis, Thomas Friess, Guy Georges, Irene Kolm, Hans-Willi Krell, Valeria Lifke, Ekkehard Moessner
  • BISPECIFIC ANTIBODIES SPECIFIC FOR FAP AND DR5, ANTIBODIES SPECIFIC FOR DR5 AND METHODS OF USE
    Publication number: 20140370019
    Abstract: The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: April 1, 2014
    Publication date: December 18, 2014
    Applicant: ROCHE GLYCART AG
    Inventors: Peter Bruenker, Sherif Daouti, Ningping Feng, Claudia Ferrara Koller, Guy Georges, Sandra Grau-Richards, Ralf Hosse, Christian Klein, Maximiliane Koenig, Joerg Moelleken, Ekkehard Moessner, Huifeng Niu, Kathryn E. Packman, Valeria Runza, Stefan Seeber, Pablo Umana, Inja Waldhauer, Huisheng Wang, Barbara Weiser
  • Antigen binding molecules with increased Fc receptor binding affinity and effector function
    Patent number: 8883980
    Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: November 11, 2014
    Assignee: Roche Glycart AG
    Inventors: Pablo Umaña, Peter Brünker, Claudia Ferrera Koller, Tobias Suter, Ursula Püntener, Ekkehard Mössner
  • COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH AN ANTI-VEGF ANTIBODY
    Publication number: 20140322200
    Abstract: The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with an anti-VEGF antibody for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and an anti-VEGF antibody.
    Type: Application
    Filed: November 27, 2013
    Publication date: October 30, 2014
    Applicant: Roche Glycart AG
    Inventors: FRANK HERTING, CHRISTIAN KLEIN
  • Anti-HER3 antibodies and uses thereof
    Patent number: 8859737
    Abstract: The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: October 14, 2014
    Assignee: Roche Glycart AG
    Inventors: Birgit Bossenmaier, Nikolaos Dimoudis, Thomas Friess, Guy Georges, Irene Kolm, Hans-Willi Krell, Valeria Lifke, Ekkehard Moessner
  • Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function
    Patent number: 8859234
    Abstract: The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to nucleic acid molecules, including fusion constructs, having catalytic activity and the use of same in glycosylation engineering of host cells to generate polypeptides with improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: October 14, 2014
    Assignee: Roche GlycArt AG
    Inventors: Pablo Umaña, Peter Bruenker, Claudia Ferrara, Tobias Suter